-- Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) raised HK$1.19 billion in net proceeds from its initial public offering in Hong Kong.
The final offer price was set at HK$27.64 per H-share, according to a Monday after-market filing with the Hong Kong Stock Exchange.
The China-based pharmaceutical firm offered 47.1 million H-shares in the global offering.
The Hong Kong public offer was 481.71 times subscribed, with a final allocation of 4.7 million shares, representing 10% of the total offering.
The international offering was 3.46 times subscribed, with a final allocation of 42.4 million shares, or 90% of the total offering.
Cornerstone investors, including Junshi Hong Kong, Sanjin International, Guohui (HK) Holdings, WuXi Biologics HealthCare Venture, and Splendid Zhonghe, were allotted a combined 15 million shares, according to the filing.
Mabwell is scheduled to debut on the Hong Kong bourse on Tuesday, April 28.